Endocrinology

In obesity and related metabolic disease, stress hormones drive lipogenesis and low-grade inflammation. Tea seed saponin tempered cortisol -triggered lipid accumulation and inflammatory signaling in human cells, reducing lipogenic and cytokine readouts unde...

In obesity, cortisol can amplify lipogenesis and low-grade inflammation across metabolic tissues. New in vitro data indicate tea seed meal saponins blunt cortisol-triggered lipid accumulation and inflammatory signaling in human cells. The key implication is...

In obesity, cortisol can amplify lipogenesis and inflammatory signaling, worsening adipose dysfunction. A saponin isolated from tea seed meal curtailed cortisol-triggered lipid build-up and pro-inflammatory mediators in human cells while preserving viabilit...

An Expression of Concern has been posted regarding work in somatotroph adenomas that linked CDKN2A (p16INK4A) to CDK inhibitors response. Because p16INK4A modulates cell cycle control, any claim that it alters anti-tumor activity is clinically relevant. The...

An expression of concern has been issued regarding CDKN2A and response to CDK inhibitors in somatotroph pituitary adenomas, raising uncertainty about a proposed biomarker mechanism. The key signal is that p16INK4A status may not yet reliably predict drug ef...

In adults with obesity exposed to vancomycin, 2'-fucosyllactose, an HMO-type prebiotic, produced a transient improvement in gut microbial resilience, accelerating early return toward baseline composition and function. Effects diminished over time, and safet...

In adults with obesity receiving vancomycin, supplementing with the human milk oligosaccharide 2'-fucosyllactose briefly enhanced gut microbial resilience, consistent with a prebiotic cross-feeding mechanism that supports community recovery. The effect was ...

In adults with obesity, antibiotics can trigger gut dysbiosis. Supplementation with the human milk oligosaccharide 2'-fucosyllactose appears to promote microbial resilience after vancomycin exposure, with benefits that are transient. This mechanism-driven, ...

The VICTORION-PLAQUE trial in primary prevention evaluates inclisiran, a small interfering RNA targeting PCSK9, for effects on atherosclerotic plaque using prespecified multimodality imaging endpoints. Randomized and double-blind, with dosing at day 1, day ...